En vivo
PfizerPfizer gets a jump on Chai's new model, thanks to drug discovery pact - FirstWord PharmaEndpoints NewsOtsuka touts new IgAN evidence as it seeks full approval for VoyxactAgilentA Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.stCharles RiverCharles River Laboratories stock (US1591881009): Insider grant and fresh fund buying keep focus on C - AD HOC NEWSEndpoints NewsActing FDA chief isn't interested in permanent roleClinical OMICsPost-Stroke Arm Immobility Improved with Spinal Cord StimulationLonza NewsStipple Bio and Lonza Agree to Focus on Advancing Oncology ADC Therapies - Genetic Engineering and Biotechnology NewsPfizerPfizer strikes $10.5 billion oncology deal with Chinese biotech - Life Sciences Intellectual Property ReviewClinical OMICsInfant Brain Development Sheds Light on Parkinson’s Link with AutismClinical OMICsAlzheimer’s Genetic Risk Loci: 16 New CandidatesEndpoints NewsActing FDA commissioner pledges to prevent political interference in rare disease meetingEndpoints NewsDimension seeks up to $750M for third life sciences fund after string of success
Agilent 19 abr 2026

KBC Group NV Has $11.17 Million Stock Holdings in Agilent Technologies, Inc. $A - MarketBeat

KBC Group NV Has $11.17 Million Stock Holdings in Agilent Technologies, Inc. $A - MarketBeat

Original
Contenido no disponible. Consulta la fuente original.